| abstract |
Compounds of formula (I) wherein X is O, CH2, S or NH, or the moiety X-R1 is hydrogen; V is CH or N; R1 is hydrogen, C¿1-6?alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heterocyclyl, heterocyclylC1-6alkyl, heteroaryl, or heteroarylC1-6alkyl any of which except for hydrogen may be optionally substituted; R?2 and R3¿ independently represent optionally substituted C¿1-6?alkyl, or R?2 and R3¿ together with the carbon atom to which they are attached form an optionally substituted C¿3-7?cycloalkyl or C3-7cycloalkenyl ring; or R?2 and R3¿ together with the carbon atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms selected from N, O, S.R?4 and R5¿ independently represent hydrogen, C¿1-6? alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heteroaryl, heteroarylC1-6alkyl, heterocyclyl, or heterocyclylC1-6alkyl, any of which except for hydrogen may be optionally substituted or R?4 and R5¿ together with the nitrogen atom to which they are attached form 4- to 8-membered ring; Ar is an aryl or heteroaryl ring either of which may be optionally substituted; one of X¿1? and X2 is N and the other is NR?6¿, wherein R6 is hydrogen, C¿1-6?alkyl, or arylC1-6alkyl or pharmaceutically acceptable salts thereof, their use as inhibitors of Raf kinases, and pharmaceutical compositions containing them. |